News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase I
Arrowhead Pharma (ARWR) Presents ARC-AAT Clinical Data At The International Liver Congress 4/24/2017
ReViral Announces Good Safety And Pharmacokinetics From Phase I Programme For RSV Antiviral RV521 In Healthy Volunteers 4/24/2017
DURECT (DRRX) Announces Presentation Of Data From A Phase Ib Study Of DUR-928 In Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress 2017 4/24/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
aTyr Pharma Announces Promising Top-Line Results From Resolaris Phase Ib/II Clinical Trial In Patients With Early Onset Facioscapulohumeral Muscular Dystrophy 4/24/2017
Cara Therapeutics (CARA) Announces Positive Data From Quantitative Phase I Trial Measuring Respiratory Safety Of I.V. CR845 4/24/2017
aTyr Pharma Presents Analyses Of Resolaris Phase Ib/II Trial In Patients With Limb Girdle Muscular Dystrophy 2B And Facioscapulohumeral Muscular Dystrophy At American Academy of Neurology 69th Annual Meeting 4/24/2017
Tiziana Life Sciences Plc Announces Publication Of Peer-Reviewed Paper From Positive Clinical Trial Of Milciclib In Patients With Refractory Solid Tumours 4/21/2017
Atara Biotherapeutics (ATRA) Announces Positive Interim Results from Ongoing Phase I Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology Annual Meeting 2017 4/21/2017
Atossa Genetics (ATOS) Receives Positive Interim Review From Independent Safety Committee In Phase I Endoxifen Dose Escalation Study 4/21/2017
Why Former Medivation (MDVN) CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant (AXON) 4/20/2017
NIH Study In The New England Journal of Medicine Shows Novartis AG (NVS) Drug Eltrombopag As First-Line Therapy With Standard Treatment Improves Responses In Severe Aplastic Anemia 4/20/2017
Phase I/II Clinical Trial Of Agenus (AGEN)' Anti-PD-1 Antibody Begins 4/20/2017
Clearside Biomedical (CLSD) Announces Completion Of Patient Enrollment In Phase I/II Open Label Clinical Trial Of CLS-TA In Diabetic Macular Edema 4/20/2017
SIGA (SIGA) Completes Enrollment And Dosing In Final Cohort Of Phase I Study Of IV Formulation Of TPOXX® (Tecovirimat) To Treat Smallpox 4/20/2017
RedHill Biopharma (RDHL) Announces Peer-Reviewed Publication Of The Positive YELIVA Phase I Study Results In Advanced Solid Tumors 4/20/2017
Oral Presentation At EASL Highlights ContraVir’s Tenofovir Exalidex (TXL) Antiviral Activity In Hepatitis B (HBV) Patients 4/20/2017
Mateon Therapeutics (MATN) Announces Initiation Of Investigator-Sponsored Phase I Study Of CA4P In Combination With Everolimus In Neuroendocrine Tumors 4/20/2017
Celsion (CLSN) Announces Presentation Of OVATION Study Findings At The Upcoming ASCO 2017 Annual Meeting 4/20/2017
BTG plc (BTG.L) Release: First European Patients Treated With Dc Bead Lumi Radiopaque Drug-Eluting Beads 4/20/2017
NIH Study In The New England Journal of Medicine Shows Novartis Drug Eltrombopag As First-Line Therapy With Standard Treatment Improves Responses In Severe Aplastic Anemia 4/20/2017
Targovax Initiates First Clinical Trial With TG02, The Second Product From Its RAS-Peptide Immunotherapy Platform 4/20/2017
Arrowhead Pharma (ARWR) Presents ARC-520 And ARC-521 Clinical Data At The International Liver Congress 4/20/2017
Prima Biomed (PRR.AX) Receives Approval For Third Cohort Of Phase I Melanoma Trial 4/20/2017
Prima Biomed (PRR.AX) Receives Approval For Third Cohort Of Phase I Melanoma Trial 4/19/2017
This Year’s Superbug Norovirus Sickens Hundreds of Millions, Prompting Urgent Race for Vaccine 4/18/2017
When It Rains, It Pours: Bay Area's OncoMed (OMED) Tanks Again as Lung Cancer Med Fails Phase II, Discontinues Phase I Study 4/18/2017
BioSpecifics Technologies Corporation (BSTC) Initiates Phase I Clinical Trial Of XIAFLEX For Treatment Of Uterine Fibroids 4/18/2017
Biogen (BIIB) Highlights Advances From Its Neurology Research Programs And Portfolio Of Innovative Medicines At AAN Congress 4/18/2017
Abide Therapeutics Announces Dosing Of First Patient In Phase Ib Study Of ABX-1431 In Tourette Syndrome And Collaboration With Tourette Association Of America 4/18/2017
WCCT Global Release: Ophthalmology Clinical Trial Results Published In Ophthalmology Journal 4/18/2017
Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported To Be A Potentiator Of Immunotherapy In An Animal Model 4/18/2017
Medicenna Treats First Patient In Phase IIb Recurrent Glioblastoma Trial 4/13/2017
Immunovaccine Announces Positive Year-Long Immunogenicity Data From Phase I Clinical Trial For Respiratory Syncytial Virus Vaccine Candidate 4/12/2017
NeuralStem Expands Phase I Safety Trial Of NSI-566 Neural Stem Cells In Spinal Injury 4/12/2017
Flugen, Inc. Raises $2M More, Provides Update on Phase I Trial 4/12/2017
3 Drug Giants That Boasts the Best Pipelines 4/11/2017
Eyevensys Receives Approval From The French Product Security Regulatory Agency ANSM To Advance Its Eyecet Platform Into Clinical Development 4/11/2017
Inovio Pharma (INO) Ebola Vaccine Demonstrates Robust Immune Responses With Favorable Safety Profile In Expanded Clinical Trial 4/11/2017
Key Milestone Reached In Catalyst Biosciences’s Subcutaneous Factor IX Program 4/11/2017
Idera Pharma (IDRA) Advances Investigational Treatment—Intratumoral IMO-2125 In Combination With Ipilimumab - For Unmet Need In Anti-PD-1 Refractory Metastatic Melanoma 4/11/2017
Inovio Pharma (INO) Ebola Vaccine Demonstrates Robust Immune Responses With Favorable Safety Profile In Expanded Clinical Trial 4/11/2017
Zika Virus: Themis Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine 4/11/2017
Alexo Announces Initiation Of Phase I Clinical Trial Of ALX148 For The Treatment Of Advanced Solid Tumors And Lymphoma 4/10/2017
Ovid Announces Initiation Of Phase I Clinical Trial Of OV101 For Adolescents With Angelman Syndrome Or Fragile X Syndrome 4/10/2017
Marinus Pharma (MRNS) Release: Ganaxolone IV Clinical Data Presented At Leading International Status Epilepticus Medical Conference 4/10/2017
Kura Oncology Doses First Patient in Phase I Trial of ERK Inhibitor KO-947 4/7/2017
Gazing Into The Crystal Ball For Advaxis (ADXS): What To Expect At ASCO 2017 4/7/2017
Galapagos (GLPG.BR) Doses First Psoriatic Arthritis Patient With Filgotinib 4/6/2017
Asceneuron Receives Regulatory Approval For Phase I Healthy Volunteer Study Of Oral Tau Inhibitor 4/6/2017
Cardiome Pharma Corp. (COM.TO)'s Partner SteadyMed (STDY) Announces Successful Completion Of Trevyent Clinical Validation Study 4/6/2017
China FDA Accepts JHL Biotech's First Clinical Trial Application 4/5/2017
PerkinElmer (PKI) Release: Phase I Clinical Trial Examines Safety Of Using Cord Blood Stem Cells For Treating Children With Autism Spectrum Disorder 4/5/2017
Spyryx Biosciences Presents Data And Corporate Update At Two Recent Conferences In Support Of Clinical Candidate For Cystic Fibrosis 4/5/2017
Agenus (AGEN) Commences Phase I Trial With Neoantigen Cancer Vaccine AutoSynVax 4/5/2017
Agenus (AGEN) Commences Phase I Trial With Neoantigen Cancer Vaccine AutoSynVax 4/5/2017
Novelion (AEGR) Release: Metreleptin And Lipodystrophy Data Presented At The Annual Meeting Of The Endocrine Society 4/5/2017
ASIT Biotech Announces That It Has Achieved The Primary Endpoint Of The Phase I/IIa Clinical Trial With Its hdm-ASIT+ Product Candidate For House Dust Mite Rhinitis 4/5/2017
ABIVAX Initiates Clinical Trial (ABX464-005) To Evaluate The Effect Of ABX464 On HIV-Reservoirs In HIV Patients 4/5/2017
Common Antibiotic May Help To Prevent Or Treat PTSD, University of Zurich Study Reveals 4/4/2017
Sorrento (SRNE) Anti-CEA CAR-T Demonstrates Promising Clinical Activity And Safety In Phase Ib Clinical Trial 4/4/2017
Replicel Life Sciences Release: Positive Results From Replicel's RCS-01 Phase I Skin Trial Are The Company's Most Compelling To Date 4/4/2017
AbbVie (ABBV) Announces Ibrutinib (IMBRUVICA) Supplemental New Drug Application For Previously Treated Chronic Graft-Versus-Host-Disease (Cgvhd) Accepted For Review By U.S. FDA 4/4/2017
Janssen R&D Release: U.S. FDA Accepts For Review The Application Of Ibrutinib (IMBRUVICA) For Chronic Graft-Versus-Host-Disease (Cgvhd) After Failure Of One Or More Lines Of Systemic Therapy 4/4/2017
XBiotech (XBIT) Reports Top-Line Results For 514G3 Antibody Therapy In Serious Staphylococcus Aureus Infections 4/4/2017
Atossa Genetics (ATOS) Enrolls First Cohort Of Eight Subjects In Endoxifen Study 4/4/2017
Corvus Pharma Announces Interim Results From Ongoing Phase I/Ib Study Demonstrating Safety And Clinical Activity Of Lead Checkpoint Inhibitor CPI-444 In Patients With Advanced Cancers 4/4/2017
RedHill Biopharma (RDHL) Receives FDA Orphan Drug Designation For YELIVA For The Treatment Of Cholangiocarcinoma 4/4/2017
Nanobiotix Expands Its Clinical Development In Head And Neck Cancer And I/O 4/4/2017
Bristol-Myers Squibb (BMY)'s Next Big Bet After Opdivo Failure—IDOs 4/4/2017
Biovica Release: DiviTum Results In Blockbuster Drug Study Presented At AACR 4/3/2017
Infinity Pharma (INFI) Release: Updated Phase 1 Data For IPI-549 Presented At AACR Annual Meeting 2017 4/3/2017
ESSA Pharma Provides Clinical Study Update And Announces Presentations At The AACR Annual Meeting 4/3/2017
BeiGene (BGNE) Presents Phase IB Data On RAF Dimer Inhibitor BGB-283 At The 2017 BeiGene (BGNE) Annual Meeting 4/3/2017
Clinical Results Presented From Prothena (PRTA)’s Phase Ib Study Of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration And Significant Reduction Of Free Serum Alpha-Synuclein In Patients With Parkinson’s Disease 4/3/2017
Bristol-Myers Squibb (BMY) Release: Five-Year Survival Observed With Opdivo (Nivolumab) In Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), In Phase 1 Study CA209-003 4/3/2017
AXON Neuroscience's Tau Vaccine Offers Potential For Treating Frontotemporal Dementia Patients 4/3/2017
Charles River  (CRL) Announces Launch Of Triple-Immunodeficient Mouse Model For Oncology Research 4/3/2017
Seattle Genetics (SGEN) Presents Data Advancing Antibody-Drug Conjugate And Novel Immuno-Oncology Programs At The AACR Annual Meeting 4/3/2017
Audentes (BOLD) Announces FDA Clearance Of Investigational New Drug Application For AT132 To Treat X-Linked Myotubular Myopathy 4/3/2017
Deciphera Release: Translational Research Results Confirm The Broad Activity Of DCC-2618 In GIST Patients With Difficult To Treat Drug Resistant KIT Mutations 4/3/2017
Data On Verastem (VSTM)’s Focal Adhesion Kinase Inhibitor Defactinib Presented At The 2017 AACR Annual Meeting 4/3/2017
Opthea Reports Positive Phase I/IIA Clinical Results For OPT-302 In Wet AMD 4/3/2017
Puma Biotech (PBYI) Presents Interim Results Of Phase Ib/II FB-10 Trial Of PB272 In Combination With Trastuzumab Emtansine (T-DM1) In HER2-Positive Metastatic Breast Cancer At The 2017 AACR Annual Meeting 4/3/2017
Oncodesign SA Presents Its Latest Scientific Developments At The AACR Annual Global Meeting On Oncology 4/3/2017
Phase I Clinical Trial Completes Using Cell Line Expertise At Cobra Biologics Ltd. 4/3/2017
Leap Therapeutics Presents Non-Clinical And Phase I Data For TRX518 And DKN-01 At The 2017 AACR Annual Meeting 4/3/2017
Halozyme (HALO) Crashed After Enrollment In Early Clinical Trials Have Been Temporarily Suspended 3/31/2017
DBV Tech, BioNet-Asia And Geneva University Hospitals Announce Phase I Trial Results Of Viaskin rPT In Pertussis Booster Vaccination 3/31/2017
Samus Therapeutics Announces Launch Of Expanded Clinical Development Programs For Novel Anti-Epichaperome Small Molecules To Diagnose And Treat Cancer And Neurodegenerative Disease 3/30/2017
Avillion Signs Clinical Co-Development Agreement With Merck & Co. (MRK) To Advance Anti IL-17 A/F Nanobody In Psoriasis 3/30/2017
Seattle Genetics (SGEN) Highlights Leadership In Antibody-Drug Conjugate Technology Innovation At AACR Annual Meeting 3/30/2017
Alzheon Presents Data To Support Selection Of Patients With Mild Alzheimer’s Disease For Pivotal Study Of ALZ-801 Using Precision Medicine Approach 3/30/2017
Aura Biosciences Announces Initiation Of Phase Ib Clinical Trial And Receipt Of FDA Fast Track Designation For AU-011 For The Treatment Of Primary Ocular Melanoma 3/30/2017
CBT Pharma Release: First-in-Human Genolimzumab Phase I Study Initiated To Assess Safety And Preliminary Efficacy In Patients With Select Advanced Solid Tumors 3/30/2017
Panacea Pharmaceuticals, Inc. Presents Data On Targeted Killing Of Leukemia Cells By Its Radiolabeled Monoclonal Antibody To The Cancer Biomarker HAAH 3/30/2017
Panacea Pharmaceuticals, Inc. Presents Data That Its Cancer Biomarker HAAH Is Readily Detectable In Serum Exosomes 3/30/2017
AbbVie (ABBV)'s New Approach To Fighting Cancer At Their Roots 3/29/2017
JHL Biotech Doses First Patient In JHL1101 Phase I European Trial 3/29/2017
ARMO BioSciences Announces First Patient Dosed In Pivotal Phase III Trial Of Immunotherapy AM0010 For Advanced Pancreatic Cancer 3/29/2017
Athenex, A U.S.-China Biopharma, Starts U.S. Trial Of Oral Chemotherapy 3/29/2017
A Look at Biogen (BIIB)'s Big Bet on the Holy Grail of Science—Alzheimer's 3/29/2017
CureLab, Inc. Publishes Results Of Phase I/IIa Clinical Trials Of Its Anti-Cancer DNA Vaccine, Elenagen 3/28/2017
Blaze Bioscience Announces Tumor Paint BLZ-100 Publication In International Journal Of Toxicology 3/28/2017
Replicel Life Sciences's Successful RCT-01 Tendon Repair Clinical Trial Shows Signs Of Healing Chronic Tendon Problems 3/28/2017
Compugen Ltd. (CGEN) Announces Lead Therapeutic Candidate COM902 For CGEN-15137/TIGIT Immuno-Oncology Program 3/28/2017
Advaxis (ADXS) Provides Phase I Data Of Higher Dose Axalimogene Filolisbac 3/27/2017
Matinas BioPharma Reports Positive Topline Data From Phase I Study Of MAT2501 3/27/2017
Nektar Therapeutics (NKTR) Initiates Clinical Study Of NKTR-358, A First-In-Class Regulatory T Cell Stimulator, Being Developed For The Treatment Of Immune And Inflammatory Disorders 3/27/2017
Matinas BioPharma's Weak Drug Pipeline And Investors With Fraudulent Histories 3/27/2017
Tarveda To Present PEN-221 Data In Small Cell Lung Cancer Models At 2017 AACR Annual Meeting 3/27/2017
Regen BioPharma Provides Update On NR2F6 Small Molecule Optimization Program For Treating Cancer And Arthritis 3/24/2017
Atossa Genetics (ATOS) Opens Enrollment In Study Of Endoxifen 3/24/2017
The Science Of Sex's 'Afterglow', Psychological Science, Study Reveals 3/24/2017
Merrimack (MACK) Initiates Phase I Study Of MM-310 In Solid Tumors 3/23/2017
FDA Provides Cornerstone Pharmaceuticals, Inc. Approval To Initiate Pivotal Study For CPI-613, Its Metabolism-Directed Anticancer Compound 3/23/2017
MediGene AG (MDGEF.PK): Announces Target And Outlines Design For Its First Clinical Trial In TCR Cancer Immunotherapy (MDG1011) 3/23/2017
PROMETRIKA To Coordinate Phase I Trial For MD Anderson Cancer Center’s Institute For Applied Cancer Science 3/23/2017
Shire (SHPG) Receives FDA Fast Track Designation For Recombinant ADAMTS13 (SHP655) For Treatment Of Hereditary Thrombotic Thrombocytopenic Purpura 3/22/2017
AVROBIO Expands Rare Disease Pipeline With Gene Therapy To Treat Gaucher Disease 3/22/2017
After Patient Death a Year Ago, Cambridge's Akashi Finally Gets the OK to Resume DMD Study 3/22/2017
Intec Pharma Initiates Phase I Trial Of Accordion Pill For Cannabinoid Therapies 3/22/2017
AVEO Oncology (AVEO) Announces First Patient Dosed In Phase I/II Tinivo Trial Of Tivozanib And Opdivo (Nivolumab) In Advanced RCC 3/22/2017
EnGeneIC Pty Ltd Doses First Patient In U.S. Phase 1 Clinical Study Of Targeted EDV Nanocells In Recurrent Glioblastoma Multiforme 3/21/2017
Blueprint Medicines (BPMC) Announces Enrollment Of First Patient In Phase 1 Clinical Trial For BLU-667 3/21/2017
Sanofi (SNY) Announces Results Of First-Of-Its-Kind Social Experiment Revealing Real-Life Impact Of Symptoms On Allergy Sufferers In The U.S. 3/21/2017
Asterias Biotherapeutics Release: Update On Full Six-Patient Cohort Confirms Patients With Complete Paralysis Can Experience Meaningful Recovery Of Function By Six Months Following AST-OPC1 Treatment 3/21/2017
Phase II/II Clinical Trial Of Apexigen's APX005M In Combination With Pembrolizumab (Keytruda) Opens For Metastatic Melanoma Patients 3/21/2017
Minoryx Therapeutics Successfully Completes Phase 1 Clinical Trial For Lead Candidate MIN-102 3/21/2017
Madison Vaccines Expands Clinical Trial Of MVI-118 For Prostate Cancer To University of Washington 3/21/2017
Helix Release: L-DOS47 Phase I Study Results To Be Presented At The 9th International Conference Of Contemporary Oncology 3/21/2017
WntResearch Announces Positive Results From Clinical Study With Drug Candidate Foxy-5 3/21/2017
Aevi Genomic Medicine (GNMX) Craters as ADHD Drug Flunks Early-Stage Study 3/20/2017
Nordic Nanovector Announces First Patient Dosed In Phase I Study Of Betalutin In Diffuse Large B-Cell Lymphoma (DLBCL), An Aggressive Form Of NHL 3/17/2017
Sonoma Pharma (OCLS) Announces Results From Sebuderm Gel Study In Treatment Of Seborrheic Dermatitis 3/16/2017
Longeveron Achieves Milestone In Groundbreaking Stem Cell Trial For Alzheimer's Disease 3/16/2017
AveXis (AVXS) SMA Gene Drug Reports Positive Data 3/16/2017
Kite Pharma (KITE) Highlights Publication From NCI Demonstrating Durable Complete Remissions In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy And Anti-CD19 CAR T-Cell Therapy 3/15/2017
Replicel Life Sciences's Phase I Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints 3/14/2017
Lung Therapeutics Doses First Patient In Phase I Clinical Trial Of LTI-01 In Australia And New Zealand 3/14/2017
ImmunoGen (IMGN) Presents Phase I Biopsy Expansion Cohort Data At The Society Of Gynecologic Oncology Annual Meeting 3/13/2017
Celltex Therapeutics Corporation Autologous Stem Cell Case Study Published In Stem Cells And Development Demonstrates Favorable Response In Pediatric Patients 3/13/2017
Edge Therapeutics Announces First Patient Randomized In Study Of Intracisternal Administration Of EG-1962 In Adults With Aneurysmal Subarachnoid Hemorrhage 3/13/2017
Heat Biologics Meets Efficacy Endpoint In Its Phase Ib Lung Cancer Trial To Progress To Phase II 3/13/2017
Late-Breaking Abstract On LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, In Combination With A PD-1 Inhibitor In An Animal Model To Be Presented At The AACR Annual Meeting 3/10/2017
Oscar Winner Turned Pharma CEO: We’ll Prevent Genital Herpes 3/10/2017
Spotlight Innovation Commences Part 2 Of Phase I Cancer Trial 3/10/2017
Synairgen (SNG.L): Additional Positive Data In Lung Fibrosis 3/10/2017
Boehringer Ingelheim Grants Orphan Drug Designation To Boehringer Ingelheim's Investigational Anti-CD33 Monoclonal Antibody BI 836858 For Treatment Of Myelodysplastic Syndromes 3/9/2017
eFFECTOR' Lead Product Candidate, Eft508, Receives Orphan Designation From FDA For Treatment Of Diffuse Large B-Cell Lymphoma 3/9/2017
CerSci Therapeutics Awarded $225K Phase I NIH SBIR Grant For The Treatment Of Neuropathic Pain 3/8/2017
Abeona Therapeutics Receives Orphan Drug Designation In The European Union For EB-101 Gene Therapy Clinical Trial For Epidermolysis Bullosa 3/8/2017
Celyad Obtains FDA Approval To Initiate The NKR-2 CAR T Cells THINK Trial In The U.S. 3/8/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders 3/8/2017
InDevR Release: VaxArray Flu Vaccine Potency Study Published In Vaccine 3/7/2017
Herantis Pharma's Clinical Study With Lymfactin Advances To High Dose Level 3/7/2017
Renown Pharma Announces Successful Results Of Apomorphine Sub-Lingual Spray Pharmacokinetic Study To Treat "OFF" Episodes In Parkinson's Patients 3/7/2017
FDA Lifts Clinical Hold On Seattle Genetics (SGEN)’ Cancer Drug Trial 3/6/2017
Concert Pharma (CNCE) Presents CTP-543 Phase I Results At American Academy of Dermatology Annual Meeting 3/6/2017
Deciphera Initiates A Phase 1 Clinical Trial Of DCC-3014 In Patients With Advanced Malignancies 3/6/2017
Mast Therapeutics (MSTX) Announces Clinical Study Of AIR001 For The Treatment Of Chronic Infection In Cystic Fibrosis Patients 3/6/2017
Cellceutix (CTIX) Provides Update On Developing P53 Drug Candidate Kevetrin As An Oral Anti-Cancer Agent 3/6/2017
Novartis AG (NVS) Puts Cancer Hopes on 4 Star Scientists Poached From Harvard Last Year 3/3/2017
Lexicon Pharma (LXRX) Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results 3/3/2017
bluebird bio (BLUE) Announces Publication Of Case Study On First Patient With Severe Sickle Cell Disease Treated With Gene Therapy In The New England Journal of Medicine 3/2/2017
Mersana Presents New Data On Investigational Cancer Antibody Drug Conjugate At AACR Annual Meeting 3/2/2017
Kite Pharma (KITE)'s CAR-T Blood Cancer Candidate Succeeds in Major Study 3/2/2017
Sangamo Therapeutics (SGMO) Receives Orphan Drug Designation From The FDA For SB-913 Genome Editing Treatment For MPS II 3/1/2017
Audentes (BOLD) Announces Commencement Of LUSTRO, A Clinical Assessment And Phase I/II Run-In Study Of Patients With Crigler-Najjar Syndrome 3/1/2017
Exelixis (EXEL) Announces Clinical Trial Collaboration With Roche (RHHBY) To Evaluate Cabozantinib And Atezolizumab In Locally Advanced Or Metastatic Solid Tumors 2/27/2017
Cellectar Biosciences  (CLRB) Provides Phase I Trial Update Of CLR 131 In Multiple Myeloma: Median Progression-Free Survival Extends To 133 Days, Median Overall Survival Reaches 17.7 Months 2/27/2017
Idera Pharma (IDRA) Presents Update From Ongoing Phase I Dose Escalation Clinical Trial Of Intratumoral IMO-2125 In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment At The 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 2/27/2017
XBiotech (XBIT) Completes Dosing Of Subjects In PK Study Being Conducted In Connection With European Marketing Application 2/27/2017
Why 2017 Will be a Data-Rich and Not Revenue-Focused Year for bluebird bio (BLUE) 2/24/2017
Galapagos (GLPG.BR) Doses First Healthy Volunteer With CF Combo GLPG2222 And GLPG2451 2/24/2017
Symic Biomedical Announces Last Patient Enrolled In SHIELD Trial Of SB-030 For Interventions In Peripheral Artery Disease 2/24/2017
Trillium Therapeutics Provides Additional Details On ASCO-SITC Conference Presentation On TTI-621 2/24/2017
MabVax Therapeutics Announces FDA Authorization To Proceed With MVT-1075 In A Phase I Clinical Trial For The Treatment Of Pancreatic Cancer 2/23/2017
Zymeworks Submits ZW25 Phase 1 Clinical Study Findings Abstract For ASCO 2017 2/23/2017
Fibrocell (FCSC) Announces Dosing Of First Patient In Phase I/II Clinical Trial Of FCX-007 Gene Therapy For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 2/23/2017
Acticor Biotech Has Selected Its Contract Research Organization To Manage Clinical Study Phase I 2/23/2017
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity Of Its Programmed Death-1 Antibody, CBT-501, At ASCO-SITC Clinical Oncology Symposium 2/23/2017
Children’s National Health System Experts To Present Data On Novel Approach To Cell Therapy For Cancer Patients 2/23/2017
Inovio Reports New Positive Clinical Data On Vaccine Advances In The Fight Against Emerging Infectious Diseases 2/23/2017
The New England Journal of Medicine Publishes Phase Ib Results For Shire (SHPG)'s Investigational Treatment For Hereditary Angioedema, A Rare Genetic Disease 2/23/2017
Matrisys Bioscience Announces Today Publication Of Highly Promising Results Which Could Translate Into Clinically Meaningful Benefits For Eighteen Million Patients With Atopic Dermatitis 2/23/2017
ImmusanT, Inc. Announces Completion Of Phase Ib Clinical Trial Of Nexvax2 For The Treatment Of Celiac Disease 2/22/2017
Immune Design Corporation (IMDZ) Receives Orphan Drug Designation For G100 Intratumoral Product Candidate 2/22/2017
ChromaDex, Inc. Release: Study Published In PAIN Reveals Nicotinamide Riboside Is An Effective Tool In Relieving Chemotherapy-Induced Peripheral Neuropathy Induced By A Common Anticancer Agent 2/22/2017
Upon Successful Completion Of Cohort 3, Cellectar Biosciences  (CLRB) Initiates Fourth Cohort Of Its Phase I Clinical Trial Of CLR 131 In Multiple Myeloma 2/22/2017
Aethlon Medical (AEMD) Reports Results Of Cytomegalovirus, Epstein-Barr And Herpes Simplex Virus Studies 2/22/2017
Chimerix (CMRX) Announces Final Data From Advise Trial Of Brincidofovir At BMT Tandem Meetings 2/22/2017
MorphoSys AG's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study With Lanthipeptide MOR107 2/21/2017
Halloran Consulting Group Advises SEEK In Preparation For First Trial Of Vaccine To Protect Against Mosquito-Borne Diseases, Including Zika And Malaria 2/21/2017
Bellicum (BLCM) Announces Initiation Of Patient Dosing With Controllable CAR T-Cell Product Candidate 2/21/2017
Protalex (PRTX) Provides Update On U.S. And EU Studies Of PRTX-100 To Treat Immune Thrombocytopenia 2/21/2017
hVIVO Services Limited Notes The Initiation Of A Phase I Clinical Trial With AGS-V, A Mosquito-Borne Disease Vaccine Candidate 2/21/2017
3 Biotechs With the Biggest and Most Promising Pipelines 2/20/2017
Nektar Therapeutics (NKTR) Release: Clinical Data From Phase I Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium 2/20/2017
Exelixis (EXEL) Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Metastatic Urothelial Carcinoma And Other Genitourinary Tumors 2/20/2017